Marisa St Claire

Prof. Marisa St Claire

NIH

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2020 in mBio
Verified
Journal Article
Open access
PDF file
YCYingyun Cai
Yingyun Cai
CYChengjin Ye
Chengjin Ye
BCBenson Cheng
Benson Cheng
ANAITOR NOGALES
AITOR NOGALES
MIMasaharu Iwasaki
Masaharu Iwasaki
Luis Martinez-SobridoLuis Martinez-Sobrido
Luis Martinez-Sobrido
Lassa virus (LASV) infects several hundred thousand people in Western Africa, resulting in many lethal Lassa fever (LF) cases. Licensed LF vaccines are not available, and anti-LF therapy is limited to off-label use of the nucleoside analog ribavirin with uncertain efficacy. We describe the generation of a novel live-attenuated LASV vaccine candidate. This vaccine candidate is based on mutating wild-type (WT) LASV in a key region of the viral genome, the glycoprotein precursor (GPC) gene. These mutations do not change the encoded GPC but interfere with its production in host cells. This mutated LASV (rLASV-GPC/CD) behaves like WT LASV (rLASV-WT) in cell culture, but in contrast to rLASV-WT, does not cause disease in inoculated guinea pigs. Guinea pigs immunized with rLASV-GPC/CD were protected against an otherwise lethal exposure to WT LASV. Our results support the testing of this candidate vaccine in nonhuman primate models ofLF.

1 June 2017
Verified
Journal Article
Closed access
MCMarisa St Claire
Marisa St Claire
DRDan R Ragland
Dan R Ragland
LBLaura Bollinger
Laura Bollinger
PJPeter B Jahrling
Peter B Jahrling

28 April 2020 in mBio
Verified
Journal Article
Open access
PDF file
YCYingyun Cai
Yingyun Cai
MIMasaharu Iwasaki
Masaharu Iwasaki
DMDaisuke Motooka
Daisuke Motooka
DLDavid X. Liu
David X. Liu
SYShuiqing Yu
Shuiqing Yu
Juan De La TorreJuan De La Torre
Juan De La Torre
Lassa virus (LASV), the causative agent of Lassa fever, infects several hundred thousand people in Western Africa, resulting in many lethal Lassa fever cases. No U.S. Food and Drug Administration-licensed countermeasures are available to prevent or treat LASV infection. We describe the generation of a novel LASV live-attenuated vaccine candidate rLASV(IGR/S-S), which is based on the replacement of the large genomic segment noncoding intergenic region (IGR) with that of the small genome segment. rLASV(IGR/S-S) is less fit in cell culture than wild-type virus and does not cause clinical signs in inoculated guinea pigs. Importantly, rLASV(IGR/S-S) protects immunized guinea pigs against an otherwise lethal exposure to LASV.

14 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
CFCourtney Finch
Courtney Finch
ICIan Crozier
Ian Crozier
JLJi Hyun Lee
Ji Hyun Lee
RBRuss Byrum
Russ Byrum
TCTimothy Cooper
Timothy Cooper
Jens H. KuhnJens H. Kuhn
Jens H. Kuhn
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing an exponentially increasing number of coronavirus disease 19 (COVID-19) cases globally. Prioritization of medical countermeasures for evaluation in randomized clinical trials is critically hindered by the lack of COVID-19 animal models that enable accurate, quantifiable, and reproducible measurement of COVID-19 pulmonary disease free from observer bias. We first used serial computed tomography (CT) to demonstrate that bilateral intrabronchial instillation of SARS-CoV-2 into crab-eating macaques ( Macaca fascicularis ) results in mild-to-moderate lung abnormalities qualitatively characteristic of subclinical or mild-to-moderate COVID-19 (e.g., ground-glass opacities with or without reticulation, paving, or alveolar consolidation, peri-bronchial thickening, linear opacities) at typical locations (peripheral>central, posterior and dependent, bilateral, multi-lobar). We then used positron emission tomography (PET) analysis to demonstrate increased FDG uptake in the CT-defined lung abnormalities and regional lymph nodes. PET/CT imaging findings appeared in all macaques as early as 2 days post-exposure, variably progressed, and subsequently resolved by 6–12 days post-exposure. Finally, we applied operator-independent, semi-automatic quantification of the volume and radiodensity of CT abnormalities as a possible primary endpoint for immediate and objective efficacy testing of candidate medical countermeasures.

9 November 2022 in Communications Biology
Verified
Journal Article
Open access
PDF file
GWGabriella Worwa
Gabriella Worwa
TCTimothy K. Cooper
Timothy K. Cooper
SYSteven Yeh
Steven Yeh
JSJessica G. Shantha
Jessica G. Shantha
AHAmanda M. W. Hischak
Amanda M. W. Hischak
ICIan Crozier
Ian Crozier
Despite increasing evidence that uveitis is common and consequential in survivors of Ebola virus disease (EVD), the host-pathogen determinants of the clinical phenotype are undefined, including the pathogenetic role of persistent viral antigen, ocular tissue-specific immune responses, and histopathologic characterization. Absent sampling of human intraocular fluids and tissues, these questions might be investigated in animal models of disease; however, challenges intrinsic to the nonhuman primate model and the animal biosafety level 4 setting have historically limited inquiry. In a rhesus monkey survivor of experimental Ebola virus (EBOV) infection, we observed and documented the clinical, virologic, immunologic, and histopathologic features of severe uveitis. Here we show the clinical natural history, resultant ocular pathology, intraocular antigen-specific antibody detection, and persistent intraocular EBOV RNA detected long after clinical resolution. The association of persistent EBOV RNA as a potential driver of severe immunopathology has pathophysiologic implications for understanding, preventing, and mitigating vision-threatening uveitis in EVD survivors.

14 July 2020 in Viruses
Verified
Journal Article
Open access
PDF file
RBRichard Bennett
Richard Bennett
JLJames Logue
James Logue
DLDavid X. Liu
David X. Liu
RRRebecca J. Reeder
Rebecca J. Reeder
KJKrisztina B. Janosko
Krisztina B. Janosko
LHLisa E. Hensley
Lisa E. Hensley
Ongoing Ebola virus disease outbreaks in the Democratic Republic of the Congo follow the largest recorded outbreak in Western Africa (2013–2016). To combat outbreaks, testing of medical countermeasures (therapeutics or vaccines) requires a well-defined, reproducible, animal model. Here we present Ebola virus disease kinetics in 24 Chinese-origin rhesus monkeys exposed intramuscularly to a highly characterized, commercially available Kikwit Ebola virus Filovirus Animal Non-Clinical Group (FANG) stock. Until reaching predetermined clinical disease endpoint criteria, six animals underwent anesthesia for repeated clinical sampling and were compared to six that did not. Groups of three animals were euthanized and necropsied on days 3, 4, 5, and 6 post-exposure, respectively. In addition, three uninfected animals served as controls. Here, we present detailed characterization of clinical and laboratory disease kinetics and complete blood counts, serum chemistries, Ebola virus titers, and disease kinetics for future medical countermeasure (MCM) study design and control data. We measured no statistical difference in hematology, chemistry values, or time to clinical endpoint in animals that were anesthetized for clinical sampling during the acute disease compared to those that were not.